Physician profile
David A Berkowitz
NPI 1134224579
$428.35
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $226.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $178.14 | 2019-2020 | |
| Daiichi Sankyo INC. | $43.32 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $42.44 | 2019 | |
| Amarin Pharma, INC. | $28.56 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $26.17 | 2019 | |
| Amgen INC. | $26.15 | 2019-2020 | |
| Novo Nordisk INC | $14.47 | 2020 | |
| Endo Pharmaceuticals INC. | $14.45 | 2020 | |
| Pfizer INC. | $14.38 | 2020 | |
| Lilly USA, LLC | $14.23 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.04 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Berkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.